A Phase I Study to Determine Safety, Tolerability and Immunogenicity of Intranasal Administration of the COVID Vaccine ChAdOx1 nCOV-19 in Healthy UK Adults
Latest Information Update: 27 Oct 2022
At a glance
- Drugs AZD 1222 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- 21 Oct 2022 Status changed from recruiting to completed.
- 18 May 2022 Planned End Date changed from 31 Mar 2022 to 30 Sep 2022.
- 18 May 2022 Planned primary completion date changed from 31 Mar 2022 to 30 Sep 2022.